Watch for the November 2026 shareholder vote and ITM-11 NDA resubmission timeline. The COMPOSE (G2/G3 GEP-NETs) interim analysis expected H1 2027 and LEVEL (lung NETs) interim analysis expected H2 2027 are key catalysts. Monitor escrow expiry (up to 15 months) for potential sell-down by ITM shareholders.
Price Chart
Executive Summary
Telix Pharmaceuticals announced a transformational merger with ITM Isotope Technologies Munich SE for US$1.65 billion upfront (cash-free/debt-free) plus up to US$700M in contingent milestones. The deal creates a vertically integrated radiopharmaceutical company with ITM's commercial-scale lutetium-177 production, a validated global distribution network, and a late-stage therapeutic pipeline including ITM-11 (177Lu-edotreotide) for GEP-NETs, which has completed Phase 3. ITM shareholders will own 23.7% of the combined entity, and the transaction is expected to close by end of FY 2026 subject to Telix shareholder approval.
Key Facts
- Upfront consideration of US$1.65 billion on a cash-free/debt-free basis; after adjustments, ITM shareholders expected to receive ~US$1.25B in Telix shares at US$11.84/share
- Additional contingent consideration of up to US$700M tied to ITM-11 regulatory approvals and FY 2030 net sales milestone
- ITM shareholders to own 23.7% of Telix shares on issue at close
- ITM reported 2025 audited revenue of US$273M, growing at ~40% CAGR from 2021-2025
- ITM manufacturing division expected to generate FY 2026 annualized EBITDA of US$106M
- Pro forma combined 2026 revenue and income expected to exceed US$1.3 billion
- Telix expects to deliver US$50M in targeted synergies in first two years
- ITM-11 received a CRL from FDA on August 7, 2026 limited to CMC and facility inspection items; resubmission is a closing condition
- COMPETE Phase 3 trial met primary endpoint: median PFS 23.9 months for ITM-11 vs 14.1 months for everolimus (HR 0.673, p=0.0223)
- Closing expected by end of FY 2026; shareholder vote expected November 2026
Financial Impact
US$1.65B upfront plus up to US$700M contingent consideration; combined pro forma revenue >US$1.3B in 2026E
Risk Factors
- Shareholder approval required; failure triggers US$5M fee plus significant transaction costs
- ITM-11 CRL remediation and resubmission timeline uncertain
- Integration risk: US$50M synergy target may not materialize
- 23.7% dilution to existing Telix shareholders
- Customer concentration risk in ITM's isotope business
- Escrow expiry could lead to significant share sell-down
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-062813 |
| Document: telix-6ktelixanditmjoinfor.htm | 0001628280-26-062813 |
| Document: a20260921telixitmasxvfin.htm | 0001628280-26-062813 |
| Document: 0001628280-26-062813-index-headers.html | 0001628280-26-062813 |
| Document: 0001628280-26-062813-index.html | 0001628280-26-062813 |
| Document: 0001628280-26-062813.txt | 0001628280-26-062813 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $9.03 (−9.97%) |
Oct 20, 2026 7d ago | Press Release | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $9.03 (−9.97%) |
Sep 29, 2026 28d ago | 6-K | $10.97 $10.72 | ▼ −2.28% | ▼ −2.46% | $9.03 (−17.68%) |
Sep 21, 2026 5w ago | 6-K | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $9.03 (−20.16%) |
Sep 20, 2026 5w ago | Press Release | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $9.03 (−20.16%) |
Sep 14, 2026 6w ago | 6-K | $12.83 $11.83 | ▼ −7.79% | ▼ −7.35% | $9.03 (−29.62%) |
Sep 14, 2026 6w ago | Press Release | $11.78 $12.83 | ▲ +8.91% | ▲ +9.37% | $9.03 (−23.34%) |
Sep 1, 2026 8w ago | 6-K | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $9.03 (−21.14%) |
Sep 1, 2026 8w ago | Press Release | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $9.03 (−21.14%) |
Aug 19, 2026 9w ago | 6-K | $12.42 $11.33 | ▼ −8.78% | ▼ −9.19% | $9.03 (−27.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers